Evidence map›Paper›PMID 22636674›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2012

Angiotensin II enhances AT1-Nox1 binding and stimulates arterial smooth muscle cell migration and proliferation through AT1, Nox1, and interleukin-18.

Anthony J Valente, Tadashi Yoshida, Subramanyam N Murthy, Siva S V P Sakamuri, Masato Katsuyama, Robert A Clark, Patrice Delafontaine, Bysani Chandrasekar

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 106 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Immune and inflammatory mechanisms in hypertension.Nature reviews. Cardiology · 2024
    Review
  9. Review
  10. Immune cells and hypertension.Immunologic research · 2024
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Vascular Stress Signaling in Hypertension.Circulation research · 2021
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Anthony J ValenteMedicine, University of Texas Health Science Center, San Antonio, USA.
Tadashi Yoshida
Subramanyam N Murthy
Siva S V P Sakamuri
Masato Katsuyama
Robert A Clark
Patrice Delafontaine
Bysani Chandrasekar
Tulane University · USKyoto Prefectural University of Medicine · JPSouth Texas Veterans Health Care System · USThe University of Texas Health Science Center at San Antonio · US

Funding

Insulin-Like Growth Factor-1and AtherosclerosisR01HL070241 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI PATRICE DELAFONTAINE · 2003 to 2026
$10.1M
ANGIOTENSIN II, IGF-1 AND SKELETAL MUSCLE ATROPHYR01HL080682 · NHLBI · UNIVERSITY OF MISSOURI-COLUMBIA · PI DELAFONTAINE, PATRICE · 2007 to 2015
$3.3M
NHLBI NIH HHS HL-70241NHLBI NIH HHS HL-80682NHLBI NIH HHS R01 HL080682
6 · The paper itself

Abstract

The redox-sensitive transcription factors NF-κB and activator protein-1 (AP-1) are critical mediators of ANG II signaling. The promitogenic and promigratory factor interleukin (IL)-18 is an NF-κB- and AP-1-responsive gene. Therefore, we investigated whether ANG II-mediated smooth muscle cell (SMC) migration and proliferation involve IL-18. ANG II induced rat carotid artery SMC migration and proliferation and IL-18 and metalloproteinase (MMP)-9 expression via ANG II type 1 (AT(1)) receptor. ANG II-induced superoxide generation, NF-κB and AP-1 activation, and IL-18 and MMP-9 induction were all markedly attenuated by losartan, diphenyleneiodonium chloride (DPI), and Nox1 knockdown. Similar to ANG II, addition of IL-18 also induced superoxide generation, activated NF-κB and AP-1, and stimulated SMC migration and proliferation, in part via Nox1, and both ANG II and IL-18 induced NOX1 transcription in an AP-1-dependent manner. AT(1) physically associates with Nox1 in SMC, and ANG II enhanced this binding. Interestingly, exogenous IL-18 neither induced AT(1) binding to Nox1 nor enhanced the ANG II-induced increase in AT(1)/Nox1 binding. Importantly, IL-18 knockdown, or pretreatment with IL-18 neutralizing antibodies, or IL-18 binding protein, all attenuated the migratory and mitogenic effects of ANG II. Continuous infusion of ANG II for 7 days induced carotid artery hyperplasia in rats via AT(1) and was associated with increased AT(1)/Nox1 binding (despite lower AT(1) levels); increased DPI-inhibitable superoxide production; increased phospho-IKKβ, JNK, p65, and c-Jun; and induction of IL-18 and MMP-9 in endothelium-denuded carotid arteries. These results indicate that IL-18 amplifies the ANG II-induced, redox-dependent inflammatory cascades by activating similar promitogenic and promigratory signal transduction pathways. The ANG II/Nox1/IL-18 pathway may be critical in hyperplastic vascular diseases, including atherosclerosis and restenosis.

Indexed as

Cell MovementCell ProliferationAngiotensin IIAngiotensin II Type 1 Receptor BlockersAnimalsCarotid ArteriesCells, CulturedGenes, ReporterHyperplasiaI-kappa B KinaseInfusion Pumps, ImplantableInfusions, SubcutaneousInterleukin-18JNK Mitogen-Activated Protein KinasesLosartanMaleAngiotensin IIAngiotensin II Type 1 Receptor BlockersI-kappa B KinaseInterleukin-18JNK Mitogen-Activated Protein KinasesLosartanMatrix Metalloproteinase 9Mmp9 protein, ratNADH, NADPH OxidoreductasesNADPH Oxidase 1NOX1 protein, ratReceptor, Angiotensin, Type 1Rela protein, ratSuperoxidesTranscription Factor AP-1Transcription Factor RelA

Identifiers

PMID22636674
PMCPMC3423158
OpenAlexW2104744985

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.